Who
Naimish Patel
Director
Company insider
Files Form 4 as: Director, AgomAb Therapeutics NV; Chief Medical Officer, CRISPR Therapeutics AG.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 3
- Bought
- $99K
- Sold
- $867K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 28 May 2024
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | AGMB AgomAb Therapeutics NVoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,328 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | AGMB AgomAb Therapeutics NVoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,328 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $211K3,786 at $55.62 | filing |
| 29 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $211K3,786 at $55.62 | filing |
| 28 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —10,000 | filing |
| 28 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —10,000 | filing |
| 28 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —10,000 | filing |
| 28 May 2026filed 1 Jun 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —10,000 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —38,499 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —38,499 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $152K3,150 at $48.26 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $152K3,150 at $48.26 | filing |
| 14 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —8,125 | filing |
| 14 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —8,125 | filing |
| 14 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —8,125 | filing |
| 14 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —8,125 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name Naimish Patel; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.